Scarica l'app Stockscreener
0.524
0.95%
-0.005
Dopo l'orario di chiusura:
.53
0.006
+1.15%
Precedente Chiudi:
$0.529
Aprire:
$0.5051
Volume 24 ore:
779.07K
Relative Volume:
0.30
Capitalizzazione di mercato:
$21.81M
Reddito:
-
Utile/perdita netta:
$-74.56M
Rapporto P/E:
-0.2861
EPS:
-1.8316
Flusso di cassa netto:
$-60.27M
1 W Prestazione:
+15.24%
1M Prestazione:
+41.62%
6M Prestazione:
-40.45%
1 anno Prestazione:
-59.69%
Intervallo 1D:
$0.49
$0.53
Intervallo di 1 settimana:
$0.4201
$0.535
Portata 52W:
$0.2201
$1.54
Rallybio Corp Stock (RLYB) Company Profile
Nome
Rallybio Corp
Settore
Industria
Telefono
203- 859-3820
Indirizzo
234 CHURCH STREET, NEW HAVEN
Confronta RLYB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
0.524 | 22.01M | 0 | -74.56M | -60.27M | -1.8316 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-09 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-05-15 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-07 | Downgrade | Jefferies | Buy → Hold |
| 2023-04-17 | Iniziato | H.C. Wainwright | Buy |
| 2023-04-10 | Iniziato | Wedbush | Outperform |
| 2022-12-09 | Iniziato | JP Morgan | Overweight |
| 2022-02-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-08-23 | Iniziato | Cowen | Outperform |
| 2021-08-23 | Iniziato | Evercore ISI | Outperform |
| 2021-08-23 | Iniziato | Jefferies | Buy |
Mostra tutto
Rallybio Corp Borsa (RLYB) Ultime notizie
Should I buy Rallybio Corporation stock before earningsFastest-growing stock picks - jammulinksnews.com
Rallybio’s RLYB116 Study: A Potential Game-Changer in Complement Inhibition - TipRanks
Rallybio Corporation Stock Analysis and ForecastMassive profits - jammulinksnews.com
Is Rallybio Corporation a good long term investmentSky-high profits - jammulinksnews.com
What analysts say about Rallybio Corporation stockHigh-octane gains - jammulinksnews.com
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - MSN
What drives Rallybio Corporation stock priceUnmatched market gains - PrintWeekIndia
Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug - MSN
10 Best Small Cap AI Stocks to Buy According to Analysts - Insider Monkey
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock - MSN
Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com
What makes Rallybio Corporation stock price move sharplyFree Best Performing Stock Alerts - Newser
Why Rallybio Corporation stock attracts strong analyst attentionFree Join Group - Newser
How Rallybio Corporation stock performs during market volatilityCarefully Curated High Return Stocks - Newser
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program - MSN
Here's Why Shares in Recursion Pharmaceuticals Surged Today - MSN
We're Keeping An Eye On Rallybio's (NASDAQ:RLYB) Cash Burn Rate - simplywall.st
Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia - Insider Monkey
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M - Yahoo Finance
Rallybio sells REV102 programme to Recursion for up to $25m - Pharmaceutical Business review -
Rallybio Drops 9.98% Despite Q1 Progress, Recursion Deal - AInvest
Rallybio sells HPP treatment program to Recursion for up to $25 million By Investing.com - Investing.com South Africa
Rallybio sells HPP treatment program to Recursion for up to $25 million - Investing.com Nigeria
Biotech Stocks Climb With Recursion's Bold Move Forward - Finimize
Recursion Pharmaceuticals stock soars after acquiring HPP treatment from Rallybio - Investing.com India
Recursion Pharmaceuticals Rises With Rallybio Acquisition Move - Finimize
Recursion, Rallybio Shares Rise After Deal on Joint Hypophosphatasia Candidate - MarketScreener
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - citybiz
RallyBio - Hartford Business Journal
Rallybio sells interest in drug program in deal worth up to $25M - Hartford Business Journal
Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Benzinga
Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement - TipRanks
Rallybio shifts gears, cashing out of Recursion pact to extend runway - Fierce Biotech
Rallybio Corp Azioni (RLYB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):